Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response.

Gao H, Korn JM, Ferretti S, Monahan JE, Wang Y, Singh M, Zhang C, Schnell C, Yang G, Zhang Y, Balbin OA, Barbe S, Cai H, Casey F, Chatterjee S, Chiang DY, Chuai S, Cogan SM, Collins SD, Dammassa E, Ebel N, Embry M, Green J, Kauffmann A, Kowal C, Leary RJ, Lehar J, Liang Y, Loo A, Lorenzana E, Robert McDonald E 3rd, McLaughlin ME, Merkin J, Meyer R, Naylor TL, Patawaran M, Reddy A, Röelli C, Ruddy DA, Salangsang F, Santacroce F, Singh AP, Tang Y, Tinetto W, Tobler S, Velazquez R, Venkatesan K, Von Arx F, Wang HQ, Wang Z, Wiesmann M, Wyss D, Xu F, Bitter H, Atadja P, Lees E, Hofmann F, Li E, Keen N, Cozens R, Jensen MR, Pryer NK, Williams JA, Sellers WR.

Nat Med. 2015 Nov;21(11):1318-25. doi: 10.1038/nm.3954. Epub 2015 Oct 19.

PMID:
26479923
2.

Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.

Fritsch C, Huang A, Chatenay-Rivauday C, Schnell C, Reddy A, Liu M, Kauffmann A, Guthy D, Erdmann D, De Pover A, Furet P, Gao H, Ferretti S, Wang Y, Trappe J, Brachmann SM, Maira SM, Wilson C, Boehm M, Garcia-Echeverria C, Chene P, Wiesmann M, Cozens R, Lehar J, Schlegel R, Caravatti G, Hofmann F, Sellers WR.

Mol Cancer Ther. 2014 May;13(5):1117-29. doi: 10.1158/1535-7163.MCT-13-0865. Epub 2014 Mar 7.

3.

JAK1/2 and Pan-deacetylase inhibitor combination therapy yields improved efficacy in preclinical mouse models of JAK2V617F-driven disease.

Evrot E, Ebel N, Romanet V, Roelli C, Andraos R, Qian Z, Dölemeyer A, Dammassa E, Sterker D, Cozens R, Hofmann F, Murakami M, Baffert F, Radimerski T.

Clin Cancer Res. 2013 Nov 15;19(22):6230-41. doi: 10.1158/1078-0432.CCR-13-0905. Epub 2013 Sep 30.

4.

Effects of a guided imagery intervention on stress in hospitalized pregnant women: a pilot study.

Jallo N, Cozens R, Smith MW, Simpson RI.

Holist Nurs Pract. 2013 May-Jun;27(3):129-39. doi: 10.1097/HNP.0b013e31828b6270.

PMID:
23580099
5.

Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging.

Schnell CR, Stauffer F, Allegrini PR, O'Reilly T, McSheehy PM, Dartois C, Stumm M, Cozens R, Littlewood-Evans A, García-Echeverría C, Maira SM.

Cancer Res. 2008 Aug 15;68(16):6598-607. doi: 10.1158/0008-5472.CAN-08-1044.

6.

NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models.

Jensen MR, Schoepfer J, Radimerski T, Massey A, Guy CT, Brueggen J, Quadt C, Buckler A, Cozens R, Drysdale MJ, Garcia-Echeverria C, Chène P.

Breast Cancer Res. 2008;10(2):R33. doi: 10.1186/bcr1996. Epub 2008 Apr 22.

7.

The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells.

Akeno-Stuart N, Croyle M, Knauf JA, Malaguarnera R, Vitagliano D, Santoro M, Stephan C, Grosios K, Wartmann M, Cozens R, Caravatti G, Fabbro D, Lane HA, Fagin JA.

Cancer Res. 2007 Jul 15;67(14):6956-64.

8.

Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases.

Lee L, Sharma S, Morgan B, Allegrini P, Schnell C, Brueggen J, Cozens R, Horsfield M, Guenther C, Steward WP, Drevs J, Lebwohl D, Wood J, McSheehy PM.

Cancer Chemother Pharmacol. 2006 Jun;57(6):761-71. Epub 2005 Sep 20.

PMID:
16172907
9.

AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.

Traxler P, Allegrini PR, Brandt R, Brueggen J, Cozens R, Fabbro D, Grosios K, Lane HA, McSheehy P, Mestan J, Meyer T, Tang C, Wartmann M, Wood J, Caravatti G.

Cancer Res. 2004 Jul 15;64(14):4931-41.

10.

In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase.

García-Echeverría C, Pearson MA, Marti A, Meyer T, Mestan J, Zimmermann J, Gao J, Brueggen J, Capraro HG, Cozens R, Evans DB, Fabbro D, Furet P, Porta DG, Liebetanz J, Martiny-Baron G, Ruetz S, Hofmann F.

Cancer Cell. 2004 Mar;5(3):231-9.

11.

Effects of epithelial growth factor receptor (EGFR) kinase inhibitors on genetically reconstituted mouse mammary glands.

Roth DR, Roman D, Cozens R, Brandt R, Seewald W, Greiner B, Wenger F, Mamom T, Germann PG.

Exp Toxicol Pathol. 2003 Nov;55(4):237-45.

PMID:
14703768
12.

Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571.

Gambacorti-Passerini C, Barni R, le Coutre P, Zucchetti M, Cabrita G, Cleris L, Rossi F, Gianazza E, Brueggen J, Cozens R, Pioltelli P, Pogliani E, Corneo G, Formelli F, D'Incalci M.

J Natl Cancer Inst. 2000 Oct 18;92(20):1641-50.

13.

New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis

Bold G, Altmann KH, Frei J, Lang M, Manley PW, Traxler P, Wietfeld B, Bruggen J, Buchdunger E, Cozens R, Ferrari S, Furet P, Hofmann F, Martiny-Baron G, Mestan J, Rosel J, Sills M, Stover D, Acemoglu F, Boss E, Emmenegger R, Lasser L, Masso E, Roth R, Schlachter C, Vetterli W.

J Med Chem. 2000 Aug 10;43(16):3200. No abstract available.

PMID:
10956229
14.

Oral bioavailability of a poorly water soluble HIV-1 protease inhibitor incorporated into pH-sensitive particles: effect of the particle size and nutritional state.

De Jaeghere F, Allémann E, Kubel F, Galli B, Cozens R, Doelker E, Gurny R.

J Control Release. 2000 Aug 10;68(2):291-8.

PMID:
10925137
15.

New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis.

Bold G, Altmann KH, Frei J, Lang M, Manley PW, Traxler P, Wietfeld B, Brüggen J, Buchdunger E, Cozens R, Ferrari S, Furet P, Hofmann F, Martiny-Baron G, Mestan J, Rösel J, Sills M, Stover D, Acemoglu F, Boss E, Emmenegger R, Lässer L, Masso E, Roth R, Schlachter C, Vetterli W.

J Med Chem. 2000 Jun 15;43(12):2310-23. Erratum in: J Med Chem 2000 Aug 10;43(16):3200.

PMID:
10882357
16.

PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.

Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J, Hofmann F, Mestan J, Mett H, O'Reilly T, Persohn E, Rösel J, Schnell C, Stover D, Theuer A, Towbin H, Wenger F, Woods-Cook K, Menrad A, Siemeister G, Schirner M, Thierauch KH, Schneider MR, Drevs J, Martiny-Baron G, Totzke F.

Cancer Res. 2000 Apr 15;60(8):2178-89.

17.

Author errata.

Lydon N, Mett H, Mueller M, Becker M, Cozens RM, Daniels D, Traxler P, Buchdunger E, Stover D.

Int J Cancer. 1999 May 17;81(4):669. No abstract available.

18.

New aza-dipeptide analogues as potent and orally absorbed HIV-1 protease inhibitors: candidates for clinical development.

Bold G, Fässler A, Capraro HG, Cozens R, Klimkait T, Lazdins J, Mestan J, Poncioni B, Rösel J, Stover D, Tintelnot-Blomley M, Acemoglu F, Beck W, Boss E, Eschbach M, Hürlimann T, Masso E, Roussel S, Ucci-Stoll K, Wyss D, Lang M.

J Med Chem. 1998 Aug 27;41(18):3387-401.

PMID:
9719591
20.

Profile of CGP 61755: a novel and potent HIV-1 protease inhibitor that shows enhanced anti-HIV activity when combined with other antiretroviral agents in vitro.

Lazdins JK, Bold G, Capraro HG, Cozens R, Fässler A, Flesch G, Klimkait T, Lang M, Mestan J, Poncioni B, Rösel J, Stover D, Tintelnot-Blomley M, Walker MR, Woods-Cook K.

Schweiz Med Wochenschr. 1996 Oct 26;126(43):1849-51.

PMID:
8916294
21.

Aza-peptide analogs as potent human immunodeficiency virus type-1 protease inhibitors with oral bioavailability.

Fässler A, Bold G, Capraro HG, Cozens R, Mestan J, Poncioni B, Rösel J, Tintelnot-Blomley M, Lang M.

J Med Chem. 1996 Aug 2;39(16):3203-16.

PMID:
8759643
22.

Synthesis of potent and orally active HIV-protease inhibitors.

Capraro HG, Bold G, Fässler A, Cozens R, Klimkait T, Lazdins J, Mestan J, Poncioni B, Rösel JL, Stover D, Lang M.

Arch Pharm (Weinheim). 1996 Jun;329(6):273-8.

PMID:
8767110
23.

pH-sensitive nanoparticles: an effective means to improve the oral delivery of HIV-1 protease inhibitors in dogs.

Leroux JC, Cozens RM, Roesel JL, Galli B, Doelker E, Gurny R.

Pharm Res. 1996 Mar;13(3):485-7. No abstract available.

PMID:
8692747
24.

Pharmacokinetics of a novel HIV-1 protease inhibitor incorporated into biodegradable or enteric nanoparticles following intravenous and oral administration to mice.

Leroux JC, Cozens R, Roesel JL, Galli B, Kubel F, Doelker E, Gurny R.

J Pharm Sci. 1995 Dec;84(12):1387-91.

PMID:
8748318
25.

CGP 53437, an orally bioavailable inhibitor of human immunodeficiency virus type 1 protease with potent antiviral activity.

Alteri E, Bold G, Cozens R, Faessler A, Klimkait T, Lang M, Lazdins J, Poncioni B, Roesel JL, Schneider P, et al.

Antimicrob Agents Chemother. 1993 Oct;37(10):2087-92.

26.
27.

9-(2-Phosphonylmethoxyethyl)adenine in the treatment of murine acquired immunodeficiency disease and opportunistic herpes simplex virus infections.

Gangemi JD, Cozens RM, De Clercq E, Balzarini J, Hochkeppel HK.

Antimicrob Agents Chemother. 1989 Nov;33(11):1864-8.

28.

Role of autolysins in the activities of imipenem and CGP 31608, a novel penem, against slowly growing bacteria.

Cozens RM, Markiewicz Z, Tuomanen E.

Antimicrob Agents Chemother. 1989 Oct;33(10):1819-21.

29.

Penems: in vitro and in vivo experiments.

Zak O, Lang M, Cozens R, Konopka EA, Mett H, Schneider P, Tosch W, Scartazzini R.

J Clin Pharmacol. 1988 Feb;28(2):128-35. Review. No abstract available.

PMID:
3283177
30.
31.

The rate of killing of Escherichia coli by beta-lactam antibiotics is strictly proportional to the rate of bacterial growth.

Tuomanen E, Cozens R, Tosch W, Zak O, Tomasz A.

J Gen Microbiol. 1986 May;132(5):1297-304.

PMID:
3534137
32.

Evaluation of the bactericidal activity of beta-lactam antibiotics on slowly growing bacteria cultured in the chemostat.

Cozens RM, Tuomanen E, Tosch W, Zak O, Suter J, Tomasz A.

Antimicrob Agents Chemother. 1986 May;29(5):797-802.

33.
34.
35.

Isolation and characterization of the outer and cytoplasmic membranes of Pseudomonas cepacia.

Anwar H, Brown MR, Cozens RM, Lambert PA.

J Gen Microbiol. 1983 Feb;129(2):499-507.

PMID:
6842182
36.

Obesity in the aged: not just a case of overeating.

Cozens RE.

Nurs Clin North Am. 1982 Jun;17(2):227-32. No abstract available.

PMID:
6919931
37.

Influence of suspending media upon the susceptibility of Pseudomonas aeruginosa NCTC 6750 and its spheroplasts to polymyxin B.

Klemperer RM, Gilbert P, Meier AM, Cozens RM, Brown MR.

Antimicrob Agents Chemother. 1979 Feb;15(2):147-51.

Supplemental Content

Loading ...
Support Center